Compare KEQU & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KEQU | AARD |
|---|---|---|
| Founded | 1906 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.3M | 97.4M |
| IPO Year | 1995 | 2025 |
| Metric | KEQU | AARD |
|---|---|---|
| Price | $32.92 | $3.94 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $11.11 |
| AVG Volume (30 Days) | 3.4K | ★ 98.3K |
| Earning Date | 12-09-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.11 |
| EPS | ★ 0.58 | N/A |
| Revenue | ★ $138,558,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $55.60 | ★ N/A |
| Revenue Growth | ★ 7.72 | N/A |
| 52 Week Low | $32.00 | $3.35 |
| 52 Week High | $46.57 | $16.60 |
| Indicator | KEQU | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 37.40 | 29.53 |
| Support Level | $32.00 | $3.38 |
| Resistance Level | $38.20 | $5.88 |
| Average True Range (ATR) | 0.55 | 0.46 |
| MACD | -0.06 | -0.10 |
| Stochastic Oscillator | 9.47 | 9.41 |
Kewaunee Scientific Corp is engaged in the design, manufacture, and installation of laboratory, healthcare, and technical furniture and infrastructure products. Its products include steel and wood casework, fume hoods, adaptable modular systems, movable workstations, stand-alone benches, biological safety cabinets, epoxy resin work surfaces, and sinks. The company operates through two reportable segments: Lab Products Group (LPG), which designs, manufactures, and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, flexible systems, work surfaces, workstations, workbenches, and computer enclosures, and the International segment.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.